NEWS & MEDIA - PRESS RELEASE 3/11/24

Lexington, MA – March 11, 2024 – Hyku Biosciences, Inc. (Hyku), a covalent precision  medicine company, today announced the appointment of Kleem Chaudhary, Ph.D. as President and Chief Executive Officer, succeeding co-founder and acting CEO Milind  Deshpande, Ph.D. who will now serve as an advisor to the company. Dr Chaudhary will  also serve as a member of the Board of Directors of Hyku. 

“I am pleased to welcome Kleem to Hyku” said Dr. Deshpande, “With his extensive  experience leading organizations and completing significant transactions across biotech  and big pharma, I am confident that Hyku will flourish under Kleem’s leadership.” 

Dr. Chaudhary brings diverse and successful experiences from his previous roles at  multiple pharma and biotech companies. Most recently, he was Chief Operating and  Business Officer at Redona Therapeutics. Prior to Redona, he was Chief Business Officer at Checkmate Pharmaceuticals, where he was instrumental in the company’s Series C  financing, IPO and led the sale of the company to Regeneron. Previously, he held  business development roles of increasing responsibility at Novartis, Takeda, and Biogen after starting his industry career as a medicinal chemist at Gilead Sciences. Dr.  Chaudhary holds a Ph.D. in chemistry from the University of North Carolina at Chapel Hill  and a B.Sc. in chemistry from the University of Winnipeg. 

“I am very impressed with the highly differentiated and innovative chemoproteomics driven drug discovery platform at Hyku that, together with the extremely talented team, has already enabled an exciting pipeline of potential first-in-class and best-in-class  medicines. Hyku’s platform has the depth and breadth to open new opportunities broadly  across therapeutic areas” said Dr. Chaudhary 

“I am delighted to welcome Kleem as the new CEO of Hyku Biosciences,” said Laura  Tadvalkar, Ph.D., Managing Director at RA Capital Management and Hyku Board  member. “Kleem’s background as a scientist and his extensive business experience  across pharma and biotech, position him to be a great partner to the board and an  excellent leader for Hyku as we advance the exciting pipeline and continue to expand and  deploy our differentiated platform.”

“Hyku’s proprietary chemoproteomics platform and precision covalent medicine pipeline  have the potential to accelerate the development of important new medicines that address  major clinical unmet needs,” said Matthias van Woensel, Ph.D., Partner at Droia Ventures  and Hyku Board member. “We are excited to have Kleem join Hyku and I look forward to  working with him to advance the exciting science at Hyku.”

About Hyku Biosciences

Hyku Biosciences is a biotechnology company, based in the greater Boston area, building the leading covalent medicines discovery platform to inhibit disease targets which are challenging to address with conventional approaches. Hyku’s drug discovery engine is based on its proprietary platform technologies, which identifies histidine, tyrosine and lysine based binding pockets and enables rational drug design for therapeutic development. The platform pioneered by Hyku has the potential to fundamentally expand the scope of small molecule drug discovery, greatly increase druggability across many target classes, and bring significant therapeutic benefits to patients via novel medicines.

For more information, please visit www.hykubiosciences.com

Contact

IR@hykubio.com